Sight Sciences announces results of CUA assessing TearCare system

Sight Sciences (SGHT) announced the results of a cost-utility analysis, CUA, assessing the cost-effectiveness of the TearCare System compared to cyclosporine 0.05%, CsA, for the treatment of moderate to severe meibomian gland disease, MGD, associated dry eye disease, DED. The analysis, published ahead of print in Expert Review of Pharmacoeconomics and Outcomes Research, demonstrated that TearCare is not only associated with greater health utility over time but also resulted in significant cost savings compared to CsA, offering a more efficient and patient-centric approach to treating this common ocular disease. Key Findings: Assuming two procedures over a 1-year time horizon, TearCare demonstrated a cost-saving advantage over CsA, reducing per-patient costs by $903 annually. Patients receiving TearCare experienced an incremental QALY gain of 0.014, compared to those on CsA.